During the past decade it has become apparent that patients can be transplanted successfully after preparation with regimens of reduced intensity. Reduced intensity preparations have resulted in lower morbidity and mortality during the pre-engraftment period, but have not reduced later occurring infections, GVHD and relapse. Outcome-determining risk factors that characterize patients at diagnosis as well as during their course include age, cytogenetic configuration, hematopoietic elements and a previous history of myelodysplasia or cytoreductive therapy for a pre-existing malignancy. These factors are complemented by the response to induction therapy and subsequent treatments as well as by the duration of the response. More recently, gene expression profiling of leukemic cells has added a new dimension to simultaneously assessed biological risk factors that may ultimately lead to individuation of therapy.
Introduction
Allogeneic blood and marrow transplants are used with the intention to achieve a cure for AML. Long-term follow-up of patients following their allogeneic transplant has indeed demonstrated disease-free survival in excess of 20 years. The procedure was originally designed to permit intensification of chemotherapy and TBI to achieve marrow ablation. The dose escalation resulted in improved disease control as initially documented in a seminal publication by the transplant team in Seattle. 1 Unfortunately, the procedure was found to be associated with significant morbidity and mortality, and even long-term survivors often experienced late effects that reduced their quality of life significantly. The applicability of transplants was therefore limited to younger patients with good performance and availability of a suitably matched donor. Unfortunately, these restrictions excluded the majority of patients suffering from AML.
The recognition that disease control after transplants was not predominantly the consequence of intensive therapy but the result of a donor cell-mediated GVL effect led to a paradigm shift that initiated a number of innovative approaches to enhance the safety of transplantation and broaden the applicability. During the past decade, it has become apparent that patients can be transplanted successfully after preparation with regimens of reduced intensity. 2 This development permitted the expansion of transplant indications to patients of older age and comorbidities that would have precluded a myeloablative transplant. Reduced-intensity preparations have resulted in lower morbidity and mortality during the pre-engraftment period. However, they have not reduced later occurring infections, GVHD and relapse. There are concerns about less effective disease control, higher rates of infections and more severe chronic GVHD.
The strategy to transplant patients with AML and the positioning of this procedure in the overall management of patients remains under constant evaluation in light of persisting transplant-related complications on the one hand and novel nontransplant approaches on the other. A number of outcome-determining risk factors have been identified that characterize patients at diagnosis as well as during their course. These parameters include age, cytogenetic configuration, hematopoietic elements and a previous history of myelodysplasia or cytoreductive therapy for a pre-existing malignancy. They are complemented by the response to induction therapy and subsequent treatments as well as by the duration of the response. More recently, gene expression profiling of leukemic cells added a new dimension to simultaneous assessed biological risk factors that may ultimately lead to individuation of therapy. 3 
Cytogenetics at presentation
A number of recent studies have confirmed the predicted value of the cytogenetic information obtained at diagnosis on patients with AML. While classifications used in Medical Research Council (MRC) or South West Oncology Grow (SWOG) trials have differed in detail, they were able to associate cytogenetic profiles with favorable, intermediate and unfavorable risk. Cytogenetic properties are predictive of remission rates, remission duration and long-term leukemia-free survival. 4, 5 Combined with other parameters such as age a predictive accuracy can be further enhanced.
It is now a common practice to assign management strategies for AML patients based on their cytogenetic configuration. Patients with favorable cytogenetic data are usually not transplanted in the first remission (CR1) but may become candidates after a relapse. In contrast, for patients with poor cytogenetics, allogeneic transplants are recommended as soon as a donor can be identified. The role of transplantation for patients with intermediate cytogenetics is less well defined. Determination of more recently defined additional molecular genetic alternations with prognostic significance may provide tools to identify subgroups of patients with intermediate risk, which should be considered for an early transplant. These parameters include internal tandem duplications of the FLT3 gene, partial tandem duplications of the MLL gene, mutations of the CEBPA and NPM1 genes as well as expressions of the BAALC, ERG and MN1 genes. [7] [8] [9] Mutations in various genes may coexist in individual patients and modify the prognosis. For instance, coexistence of the MPM1 mutation with FLT3 wild-type results in better overall survival (OS) compared to patients presenting with FLT3 internal tandem duplications in the absence of NMP1 mutations. 7 If confirmed, these and other parameters have the potential to form the basis for treatment strategies that include all options with optimal timing.
A number of studies have addressed the question whether or not transplants are able to overcome the impact of unfavorable cytogenetics on survival. The majority of studies confirmed that cytogenetic risk at diagnosis retains its predictive value even after transplantation. [10] [11] [12] [13] The difference in the various cytogenetic risk categories was related to differences in the relapse rate. One report by a single center did not detect a difference in survival for patients with different cytogenetic risk group when transplanted in CR1.
14 A recent study limited to transplants from matched unrelated donors also failed to demonstrate a difference in survival for patients with different cytogenetic risk. 15 The relatively low survival of the whole cohort may obscure any potential difference. A direct comparison of 1198 patients with AML aged less than 46 years, which presented with or without donors resulted in the observation that patients in the unfavorable cytogenetic risk group with donors derived a significant benefit in OS, disease-free survival and the time of relapse compared with patients without donors. 16 A difference was not observed for patients in the favorable or intermediate risk category. The date from this study and four other large series were examined in a meta-analysis. 17 The analysis was designed to include studies that evaluated the outcome of patients with AML and CR1 by the availability of a related donor using an intention-to-treat approach. Four of the studies had demonstrated a benefit with respect to EFS in favor of patients with donors but none had shown a benefit in OS. The meta-analysis demonstrated an advantage in OS for the whole cohort of patients with donors. When examined by cytogenetic risk group, a significant advantage was observed for patients with donors that presented with unfavorable risk. The favorable risk group with donors did not derive a survival benefit. The impact on patients with intermediate risk cytogenetic was not significant. On the basis of currently available information, it is therefore reasonable to offer allogeneic transplants at least for patients presenting with unfavorable cytogenetics.
Response to therapy as indicator of risk
Patients with AML that maintain a high blast count within the first 2 weeks after initiation of remission induction therapy and primary induction failures are generally known to have a poor prognosis. Some patients will respond to conservative salvage therapy and a small number of patients in this category will derive benefits from an allograft even if performed with persisting disease. 18, 19 Unfortunately, the majority of patients will relapse and future efforts will have to focus further post-transplant interventions.
Patients that have relapsed after achieving a CR1 are generally managed with salvage therapy and are then usually considered for a transplant. Again, the question is raised whether or not all patients should be offered a transplant or whether this option should be reserved for patients with particularly high risk. A study that enrolled 1560 patients with AML at diagnosis was designed to address these issues. 20 A total of 667 patients relapsed and were assessed for risk factors. A prognostic score was developed based on the relapse interval from the CR1, cytogenetic profile at diagnosis, age at relapse and performance of the SCT before relapse. The prognostic score was able to discriminate groups of patients with significant differences in OS following salvage therapy. The 5-year survival of patients representing the lowest risk score approximated 50% compared with 5% for patients with the highest risk score. Using this scoring system, the question was investigated whether or not different salvage strategies impact on survival. Irrespective of risk categories, recipients of allograft had significantly better survival at 5 years than patients receiving chemotherapy alone or chemotherapy followed by autologous transplants.
Age
Age is a well-established risk factor for patients with AML. It was examined independent of other risk factors. The 5-year survival of patients below the age of 50 years treated with conservative therapy amounts to approximately 50% followed by a reduction to 35, 20 and 10% for the following decades. 6 For patients with complex cytogenetic abnormalities at the diagnosis, the respective 2-year survival figures are as low as 35% for patients below the age of 50 years and approximately 0-10% for all other age categories. This group of patients is clearly in need of a novel therapeutic approach that takes into count the increased treatmentrelated morbidity and mortality observed for patients with increasing age following myeloblative transplants.
A novel approach was recently piloted for selected patients with AML above the age of 60 years with previously untreated leukemia, primary induction failure or relapse. Transplanted from related or unrelated donors following a nonmyeloblative preparation, these patients achieved an OS and EFS of 70 and 62%, respectively, with acceptable treatment-related morbidity of 20% at 2 years. 21 These data were confirmed in the subsequent report that included 34 patients. With a median follow-up of 913 days, the survivor of 65% is significantly better than that achieved by any other currently applied therapeutic strategies. 22 A control study will be mandatory to assess general applicability of this approach and exclude any potential selection basis.
Choice of donors
The outcome of transplants using unrelated donors has continued to improve, and the data now approach those observed with matched sibling donors.
The effect of using related or unrelated donors was prospectively examined for patients with AML that presented with high-risk disease based on their initial cytogenetic data and the blast counts in BM samples obtained 15 days after remission induction. A total of 234 patients with high-risk parameters were enrolled into the study. 23 One hundred and thirty-seven (58%) achieved a CR. After consolidation therapy, 34 patients received an allograft from matched sibling and 29 from an unrelated donor. It is of note that 26 patients for whom a donor could not be identified received an autotransplant. The 4-year survival was 68% for a matched related transplant, 56% for unrelated transplant and 26% for recipients of an autograft. This study confirmed that high-risk patients with AML should be given the opportunity for a transplant using a matched unrelated donor in the absence of a related donor.
Preparative regimens
One of the main limitations of allogeneic transplants is the consequence of the high treatment-related morbidity and mortality. As mentioned above, this problem has been approached through the development of nonmyeloablative preparative regimens. A recent review 24 of a large study on 834 patients transplanted following preparation with TBI at a dose of 200 cGy with or with out fludarabine at 30 mg/m 2 /day Â 3 days included 152 patients with AML. The relapse rate per patient year was 33% for patients transplanted in CR1 and 37% for patients transplanted in second or higher CR. Patients not in remission had a substantially higher relapse rate of 87%. Patients relapsing after a transplant ultimately fail their treatment and the question has to be asked whether or not more effective regimens can be developed that are associated with lower and more tolerable toxicity. A recently published myeloablative regimen 25 combining antithymocyte globulin (ATG), fludarabine and Bu has resulted in an 83% overall and disease-free survival in patients with AML up to 5 years. The regimen was fairly well tolerated and likely is acceptable to patients up to the age 60 years. If confirmed, in larger studies and longer follow-up, this regimen has the potential to become a new standard in the preparation of transplant recipients.
Management of patients relapsing after an allograft
Patients relapsing after allografting generally tend to have a poor outcome. Treatment approaches including rapid discontinuation of immunosuppression, infusion of donor leukocytes, salvage with chemotherapy and second transplants are of limited success. The majority of patients has a poor outcome with a median survival of 2-3 months. Only patients able to tolerate a second allograft or donor leukocyte infusions (DLI) may experience some prolonged survival.
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Conclusion
The role of allogeneic blood and marrow transplants in the management of patients with AML remains under continuous re-evaluation. The prime objective of any novel transplant-related approach is the reduction of the procedure-related toxicity and maintenance of the antileukemia effect. While transplants with reduced-intensity preparative regimens have facilitated the expansion of the indications to patients of older age and more severe comorbidity, their effectiveness remains hampered by a significant relapse rate for patients with a high risk of disease. There are encouraging new developments with respect to less toxic myeloablative regimens, particularly, if high-dose TBI and Cy can be avoided. One of the new developments combines ATG, fludarabine, Bu and TBI at 400 cGy. The encouraging results require confirmation in a multiple center setting with inclusion of unrelated donors. Confirmation of an 85% prolonged survival would reposition the role allogeneic transplantation as the most effective management of patients with AML independent of other risk factors.
